Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.35 |
| ▸ | COPS5 | Q92905 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CD44 | P16070 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2687017 | 0.82 | GABRA1 (0.48) | GABRA1GABRB2CYP2A6CYP1A2TRPA1 | |
| SCHEMBL8387574 | 0.82 | GABRA1 (0.48) | GABRA1GABRB2CYP2A6CYP1A2TRPA1 | |
| SCHEMBL942704 | 0.81 | CYP2A6 (0.36) | GABRA1GABRB2CYP2A6CYP1A2TRPA1 | |
| SCHEMBL28225311 | 0.78 | PSMD14 (0.32) | PSMD14COPS5 | |
| SCHEMBL25514646 | 0.77 | — | — | |
| SCHEMBL4988860 | 0.76 | CA2 (0.46) | GABRA1GABRB2TSHRCA2ALDH1A1 | |
| SCHEMBL27943107 | 0.76 | GABRA1 (0.40) | GABRA1GABRB2CYP2A6CYP1A2TRPA1 | |
| SCHEMBL1927917 | 0.73 | GABRA1 (0.58) | GABRA1GABRB2CYP2A6CYP1A2TRPA1 | |
| SCHEMBL16355401 | 0.73 | GABRA1 (0.47) | GABRA1GABRB2CYP2A6CYP1A2TRPA1 | |
| SCHEMBL9607578 | 0.71 | CD44 (0.52) | GABRA1GABRB2CYP2A6CYP1A2TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2243668-A | — | — | None | — | — | JP | disclosed |
| US-8119103-B2 | Bifunctional resorcinol, thioresorcinol, and dithioresorcinol derivative metal chelating conjugates | MALLINCKRODT LLC (US) | 2012-02-21 | — | — | US | disclosed |
| US-7550639-B2 | Process for producing olefin oligomer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-06-23 | — | — | US | disclosed |
| US-7323611-B2 | Process for producing olefin oligomer | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2008-01-29 | — | — | US | disclosed |
| US-7186667-B2 | Catalyst component and catalyst for addition polymerization, and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-03-06 | — | — | US | disclosed |
| US-20070027350-A1 | PROCESS FOR PRODUCING OLEFIN OLIGOMER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-02-01 | — | — | US | disclosed |
| US-20060293546-A1 | PROCESS FOR PRODUCING OLEFIN OLIGOMER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-12-28 | — | — | US | disclosed |
| US-7115539-B2 | Metal compound, and catalyst component and catalyst for addition polymerization, and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2006-10-03 | — | — | US | disclosed |
| US-7084219-B2 | Contact product, and catalyst component and catalyst for addition polymerization, and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-08-01 | — | — | US | disclosed |
| US-20040209762-A1 | Metal compound, and catalyst component and catalyst for addition polymerization, and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-10-21 | — | — | US | disclosed |
| US-20040209767-A1 | Contact product, and catalyst component and catalyst for addition polymerization, and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-10-21 | — | — | US | disclosed |
| US-20040186009-A1 | Catalyst component and catalyst for addition polymerization, and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-09-23 | — | — | US | disclosed |
| US-6548443-B1 | A transition metal compound having a cyclopentadiene in its molecule with a modified aluminum oxy compound obtained by reacting an aluminum oxy with a compound having a hydroxyl; improvement of the catalyst activity | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-04-15 | — | — | US | disclosed |
| US-20010053832-A1 | Olefin polymerization catalyst and process for producing olefin polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-12-20 | — | — | US | disclosed |
| EP-1134234-A1 | Olefin polymerization catalyst and process for producing olefin polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-09-19 | — | — | EP | disclosed |
| EP-1081167-A1 | Olefin polymerization catalyst and process for producing olefin polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-03-07 | — | — | EP | disclosed |
| JP-H02243668-A | METHYL-2-TERT-BUTYL-5-THIOPHENOL AND ITS PRODUCTION AND USE THEREOF | SOC FR HOECHST | 1990-09-27 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209762-A1 | Metal compound, and catalyst component and catalyst for addition polymerization, and process for producing addition polymer | AP1M1, PYM1, SEM1 | GABRA1 4006/4885GABRB2 4485/4885CYP2A6 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.